Early aortic valve replacement (AVR) significantly lowered the risk of operative or cardiovascular (CV) death compared with conservative care in asymptomatic patients with very severe aortic stenosis (AS), according to the RECOVERY* trial presented at AHA 2019, thus providing support for early intervention before symptoms for valvular disease surface.
Rivaroxaban treatment after successful transcatheter aortic valve replacement (TAVR) for aortic valve stenosis is linked to an increased risk of death, thromboembolic events, and bleeding in patients without an indication for oral anticoagulation, results of the GALILEO* trial showed.
The anti-inflammatory drug colchicine at a dose of 0.5 mg/day significantly reduced the risk of ischaemic cardiovascular (CV) events in individuals with a recent myocardial infarction (MI), according to results of the COLCOT* trial presented at AHA 2019.
Use of the PCSK9* inhibitor alirocumab in acute coronary syndrome (ACS) patients on a background of high-intensity statin treatment delivers reductions in total hospitalizations and death with corresponding gains in days alive and out of hospital (DAOH), according to the results of prespecified and posthoc analyses of the ODYSSEY OUTCOMES** trial presented at the American Heart Association (AHA) 2019 Scientific Sessions.
Treatment with the PCSK9 inhibitor alirocumab reduces the risk of stroke in patients with recent acute coronary syndrome (ACS) and dyslipidaemia despite intensive statin therapy, regardless of their baseline low-density lipoprotein cholesterol (LDL-C) and history of cerebrovascular disease (CeVD), according to the results of the ODYSSEY OUTCOMES trial presented at the 2019 Scientific Sessions of the American Heart Association.
Patients who suffer from respiratory failure before and after implantation of left ventricular access devices (LVADs) have worse survival, according to a recent study presented at the 2019 Scientific Sessions of the American Heart Association (AHA 2019).
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.